Hormonal
Pharmacological blockade of central melanocortin receptors (CNS-Mcr) directly promotes lipid uptake, triglyceride synthesis, and fat accumulation in white adipose tissue (WAT) independent of food intake.
If you have genetic or hormonal factors that impair your brain's ability to signal fat storage (like MC4R mutations), your body may store fat more aggressively even if you eat the same amount as others. This isn't a failure of willpower; it's a biological signal. Understanding this can help shift focus from just 'eating less' to addressing underlying metabolic health and hormonal balance.
We report that pharmacological inhibition of melanocortin receptors (Mcr) in rats and genetic disruption of Mc4r in mice directly and potently promoted lipid uptake, triglyceride synthesis, and fat accumulation in white adipose tissue (WAT), while increased CNS-Mcr signaling triggered lipid mobilization. These effects were independent of food intake and preceded changes in adiposity.
Why this rating
Strong pharmacological and genetic evidence in rodent models, supported by human genetic data, but limited by species differences.
Source
The central melanocortin system directly controls peripheral lipid metabolism
Rubén Nogueiras et al. · Journal of Clinical Investigation · 2007
DOI 10.1172/jci31743
More from this paper
- Activation of central melanocortin receptors increases sympathetic nerve activity to white adipose tissue, leading to lipid mobilization and reduced fat storage.Good
- Blockade of central melanocortin receptors decreases glucose utilization in skeletal muscle and brown adipose tissue while increasing glucose uptake in white adipose tissue.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →